An analysis of the use of targeted therapies in patients with advanced Merkel cell carcinoma and an evaluation of genomic correlates of response

ConclusionIn our series, targeted agents elicited a disease control rate of 19% in patients with advanced MCC, with a best overall response of SD. Pazopanib alone or in combination exhibited a rate of disease control of 36% (4 of 11 with SD ≥6 months).

Source: Cancer Medicine - July 16, 2021 Category: Cancer & Oncology Authors: Todd C. Knepper, Robyn A. Panchaud, Elnara Muradova, Leah Cohen, James A. DeCaprio, Nikhil I. Khushalani, Kenneth Y. Tsai, Andrew S. Brohl Tags: ORIGINAL RESEARCH Source Type: research